After a Big Win, Is Sarepta Therapeutics Stock a Buy? [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy (DMD), Elevidys, from an accelerated approval to a full approval. It also provisionally included a wider set of patients than it did originally. The biotech will now have a larger market, and the risk of a regulatory blockade damaging its stock has been downgraded. Nonetheless, trouble could be brewing, and you need to consider the situation carefully before making an investment, or perhaps avoid buying the stock at all. Here's why this recent win may not be as promising as it it might appear. This victory is controversial for good reason Make no mistake. For the near term, it's bullish that Sarepta received full approval for Elevidys as well as the expanded label that it had sought. Sales of the therapy were worth $134 million in the first quarter of 2024, marking a total of $334 million in revenue since its approval in June 2023. Those sales now have a clear path to continue growing for even
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Royal Bank of Canada from $181.00 to $182.00. They now have an "outperform" rating on the stock.MarketBeat
- Exploring High Growth Tech Stocks This October 2024 [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks To Watch This October 2024 [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- High Growth Tech Stocks to Watch in September 2024 [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 8/7/24 - Beat
SRPT
Sec Filings
- 9/16/24 - Form 4
- 9/16/24 - Form 3
- 9/16/24 - Form 8-K
- SRPT's page on the SEC website